Description

3H-Cyclopenta[B]Benzofuran-5-Carboxylic Acid, 7-Bromo-3A,8B-Dihydro-, cis-(-)- is a high-purity, advanced pharmaceutical intermediate characterized by its specific stereochemistry and functional groups. This compound is critical for research and development in medicinal chemistry, particularly in the synthesis of novel active pharmaceutical ingredients (APIs). It is primarily sought by pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) engaged in the development of complex small-molecule therapeutics.

Application

• Pharmaceutical Intermediate: A key chiral building block in the multi-step synthesis of complex drug candidates, particularly those targeting central nervous system (CNS) disorders.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies and lead optimization programs to explore new chemical entities.
• Process Chemistry Development: Serves as a critical starting material or intermediate in scaling up synthetic routes from laboratory to pilot plant scale.
• Asymmetric Synthesis: Utilized in chiral synthesis due to its defined cis-(-) stereochemistry, enabling the construction of enantiomerically pure targets.
• Academic Research: Employed in university and institutional labs for studying novel heterocyclic chemistry and reaction mechanisms.

Basic Information

Product Name	3H-Cyclopenta[B]Benzofuran-5-Carboxylic Acid, 7-Bromo-3A,8B-Dihydro-, cis-(-)-
CAS No.	88277-50-3
Molecular Formula	C12H9BrO3
Molecular Weight	281.10 g/mol
Synonyms	7-Bromo-3a,8b-dihydro-3H-cyclopenta[b]benzofuran-5-carboxylic acid, cis-(-)-; (-)-7-Bromo-3a,8b-dihydro-3H-cyclopenta[b]benzofuran-5-carboxylic acid; cis-(-)-7-Bromo-3a,8b-dihydro-3H-cyclopenta[b]benzofuran-5-carboxylic acid; 7-Bromo-cis-(-)-3a,8b-dihydro-3H-cyclopenta[b]benzofuran-5-carboxylic acid; 88277-50-3; (3aR,8bS)-7-Bromo-3a,8b-dihydro-3H-cyclopenta[b]benzofuran-5-carboxylic acid (enantiomer-specific IUPAC).
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems. Each batch is subjected to rigorous analytical testing, including chiral HPLC, NMR, and mass spectrometry, to ensure high chemical and enantiomeric purity. A comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles is provided with every shipment. Our quality standards are designed to meet the demanding requirements of cGMP (current Good Manufacturing Practice) for pharmaceutical development.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). The compound may be light-sensitive; prolonged exposure to light should be avoided. Keep the container tightly sealed in a dry environment to maintain stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Enantiomeric Excess (Chiral HPLC)	≥ 99.0%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	< 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.